A review article, by Katya Chobotova, discusses molecular mechanisms linking ageing and cancer. While the author discusses many areas that are typically encountered surveys of molecular mechanisms, such as oxidative stress, DNA damage, and stem cells, a particularly interesting feature of this review is an examination of the role that psychological stress may play at a molecular level, as well as the potential benefits of stress relief methods and exercise.
This article is followed by three experimental studies in the area of physical care of cancer patients. James Mao and colleagues, at the University of Pennsylvania, present a pilot study of electro-acupuncture in arthralgia caused by the use of aromatase inhibitors by breast cancer patients. Considering the large number of breast cancer survivors who are taking these drugs, and the very high potential for functional impairment as well as discontinuation of treatment, their positive findings for electroacupuncture are a significant step forward.
Claudio Battaglini and colleagues at the University of North Carolina showed reduced fatigue and depression in a feasibility study of leukemia patients undergoing stem cell transplants. They used prescriptive individualized exercise routines, which included recumbent ergometers, strength training, and core exercises, and importantly, demonstrated the feasibility of exercise interventions of this type in a setting where infection control and adaptation to the needs of high-risk patients are a necessity.
Elizabeth Evans and colleagues, also at the University of North Carolina, assessed physiological responses to exercise in posttreatment breast cancer patients and healthy controls. As more and more studies of exercise in cancer patients are completed, it is becoming clear that exercise is of great benefit in cancer. However, questions have arisen about whether exercise might compromise certain classes of patients and researchers are now beginning to explore whether such theoretical risks might be real. This is an obvious concern with breast cancer patients who may be treated with anthracyclines or trastuzumab, both of which are cardiotoxic. The study by Evans, which found that breast cancer patients were similar to normal volunteers in most outcome measures, will help in the process of determining how to individualize exercise recommendations for cancer patient populations.
The lacquer tree, Rhus verniciflua, is used in traditional medicine in Korea. Seong-Woo Yoon and colleagues, at Kyung Hee University, have studied a standardized extract T he recent compelling studies demonstrating that prostate specific antigen (PSA) screening saves few, if any, lives reminds us of the hormone replacement therapy controversy of a few years ago. Briefly, two major studies, one conducted in the US and one in Europe, both found that PSA screening programs added little, if anything, to our ability to save lives. The study conducted in the United States found that prostate cancer death rates did not differ significantly between patients who were screened and those who were not screened, while the European study found that screening did reduce death rate, but only by 20%, meaning a reduction in overall death rates from 3% to 2.4%. Furthermore, this study found that for each man who was helped by PSA screening, nearly 50 individuals received treatments that were not necessary and that increased risk for side effects such as impotence. This spurred Dr Otis Brawley, medical director of the American Cancer Society, to say in the New York Times that "the test is about 50 times more likely to ruin your life than it is to save your life." 1 Thus, PSA screening, which had virtually become standard as a prevention measure, is shown to be dangerous in much the same way that hormone replacement therapy to alleviate menopausal symptoms in women was found to increase disease risk (although PSA remains a necessary tumor marker for monitoring disease progression in patients with active disease). This is certainly a warning to the conventional medicine world to remember to maintain an attitude of humility. It also, of course, represents a welcome challenge to the world of integrative medicine where disease prevention through diet and exercise may contribute much more to our health than disease "prevention" through screening tests and medication.
This issue begins with a letter to the editor in response to an article by Hwa-Seng Yoo and colleagues in the September, 2008 issue of the journal. We are pleased to see this response to a previous article and encourage readers to respond to other articles in the future. Farah Zia and Jeff White of the National Cancer Institute (NCI) respond to comments made by Dr Woo in his article on the NCI's Best Case Series program, explaining the rationale that NCI uses for selection of best cases. of this plant in advanced colon cancer patients. The lacquer tree is a member of the plant family Anacardiaceae, known for toxic and irritating compounds in a number of its members (readers in the Americas may be familiar with poison oak and poison ivy, which are in the same genus as the lacquer tree). Use of a Rhus species medicinally is certain to trigger alarm in the minds of those familiar with its phytochemistry. The irritating and allergenic compounds in Rhus species are found in the component urushiol, a mixture of catechol derivatives. The extract used by Yoon and colleagues, however, is urushiol-free. An interesting description of the method of extraction and standardization can be found in their article. With the urushiol removed, the extract caused few and minor adverse effects in this study and was associated with positive survival effects.
Johanna Hok, Anette Forss (sharing first authorship), and colleagues at the Karolinska Institute in Stockholm, present a qualitative study of a phenomenon that has been important in the emerging role of complementary and alternative medicine (CAM) in cancer care-the "exceptional" cancer patient. Stories of exceptional cancer patients play a role in everything from advertisements for alternative cancer patients to the NCI's Best Case Series mentioned above. Hok, Forss, and colleagues examined the cases of several potential exceptional cancer patients from the viewpoints of patients, CAM providers, and physicians, using qualitative methods to explore their thought processes on the concept of exceptionality. They naturally found conflict and disagreement among the different stakeholders about the idea of exceptionality. Interestingly, the letter by Zia and White in the current issue replays this disagreement about exceptionality at a scientific level, illustrating the continuing importance of this concept.
Heather Zwickey and colleagues, at the Helfgott Research Institute at the National College of Naturopathic Medicine in Portland, Oregon, contribute a case study to this issue involving escharotic treatment of cervical intraepithelial neoplasia. While the patient involved had a lesion that was of sufficient medical concern to definitely warrant medical treatment, and was advised to seek conventional excision, she refused to receive any further medical treatment. Patients who refuse recommended medical treatment are a dilemma for conventional medicine. The patient in this case was treated with botanical escharotics and an oral vitamin and antioxidant regimen, with good long-term results. It is also an intriguing demonstration of a less invasive technique of treating cervical lesions that may deserve further exploration.
Aleksandra Niedzwiecki and colleagues, at the Dr Rath Research Institute in Santa Clara, California, examined the effect of a mixture of amino acids, vitamin C, and green tea extract on the growth and metastatic potential of head and neck squamous cell carcinoma in an in vivo and in vitro study. The successful inhibition of both growth and metastasis, apparently accomplished at least in part through the inhibition of matrix metalloproteinases, shows the potential promise of this mixture. Of particular note, in contrast to conventional chemotherapy, the mixture appears to be nontoxic, based on results of a previous in vivo study, and may be given in amounts greatly exceeding normal intake of these nutrients.
Upendra Rawal and colleagues, at the Gujarat University, studied the potential of andrographolide, a phytochemical from the Indian medicinal plant Andrographis paniculata, to reverse liver damage due to the carcinogen hexachlorocyclohexane. They observed the reactivation of several liver enzymes in mice treated with the carcinogenic compound as well as andrographolide. Andrographolide has been found in several other studies to have application in liver damage, and its plant source is one of a large number of traditional Indian medicines that are recommended for liver conditions. Kuzhuvelil Harikumar and colleagues, at Amala Cancer Research Institute, examined another Indian medicinal plant used for liver conditions, Phyllanthus amarus. However, this study did not concern liver toxicity, but rather the potential effect of this species on lymphoma. They report that the extract induced apoptosis, noting also induction of caspase-3 and inhibition of Bcl-2, both activities that would tend to promote apoptosis. As is the case with many herbal extracts, this plant appears to have a wide range of potential medicinal applications.
It is a pleasure to see that Integrative Cancer Therapies is receiving a steady stream of articles on a wide crosssection of potential therapeutic approaches, and from a truly global roster of authors. We hope to see this continue and urge our readers and contributors to consider sending high-quality articles. As a reminder, all submissions should be sent directly through our electronic portal, SageTrack, at http://mc.manuscriptcentral.com/ict. Our editorial staff will assist authors with the submission process should any problems be encountered.
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